RIGL vs. TGTX
RIGL (Rigel Pharmaceuticals, Inc.) and TGTX (TG Therapeutics, Inc.) are both stocks. Both operate in the Biotechnology industry within the Healthcare sector. Over the past 10 years, RIGL returned 3.28%/yr vs 21.61%/yr for TGTX. At a 0.31 correlation, their price movements are largely independent.
Performance
RIGL vs. TGTX - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, RIGL achieves a -23.30% return, which is significantly lower than TGTX's 66.12% return. Over the past 10 years, RIGL has underperformed TGTX with an annualized return of 3.28%, while TGTX has yielded a comparatively higher 21.61% annualized return.
RIGL
- 1D
- 2.40%
- 1M
- 2.24%
- YTD
- -23.30%
- 6M
- -19.45%
- 1Y
- 54.23%
- 3Y*
- 27.10%
- 5Y*
- -3.96%
- 10Y*
- 3.28%
TGTX
- 1D
- 3.06%
- 1M
- 16.11%
- YTD
- 66.12%
- 6M
- 57.96%
- 1Y
- 32.51%
- 3Y*
- 21.69%
- 5Y*
- 5.57%
- 10Y*
- 21.61%
RIGL vs. TGTX - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
RIGL Rigel Pharmaceuticals, Inc. | -23.30% | 154.64% | 16.00% | -3.33% | -43.40% | -24.29% | 63.55% | -6.96% | -40.72% | 63.03% |
TGTX TG Therapeutics, Inc. | 66.12% | -0.96% | 76.23% | 44.38% | -37.74% | -63.48% | 368.65% | 170.73% | -50.00% | 76.34% |
Correlation
The correlation between RIGL and TGTX is 0.33, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.33 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.35 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.38 |
Correlation (10Y) Calculated over the trailing 10-year period | 0.38 |
Correlation (All Time) Calculated using the full available price history since May 3, 2010 | 0.31 |
Fundamentals
RIGL:
$646.69M
TGTX:
$7.93B
RIGL:
$19.21
TGTX:
$2.87
RIGL:
1.71
TGTX:
17.23
RIGL:
0.00
TGTX:
0.03
RIGL:
2.08
TGTX:
11.37
RIGL:
1.62
TGTX:
13.59
RIGL:
$299.77M
TGTX:
$700.35M
RIGL:
$279.95M
TGTX:
$581.54M
RIGL:
$125.80M
TGTX:
$156.88M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
RIGL vs. TGTX — Risk / Return Rank
RIGL
TGTX
RIGL vs. TGTX - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Rigel Pharmaceuticals, Inc. (RIGL) and TG Therapeutics, Inc. (TGTX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| RIGL | TGTX | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +0.09 | ||
| Sortino ratioReturn per unit of downside risk | +0.35 | ||
| Omega ratioGain probability vs. loss probability | 1.20 | 1.16 | +0.04 |
| Calmar ratioReturn relative to maximum drawdown | 1.09 | 1.00 | +0.09 |
| Martin ratioReturn relative to average drawdown | 1.91 | 1.81 | +0.10 |
Loading charts...
Drawdowns
RIGL vs. TGTX - Drawdown Comparison
The maximum RIGL drawdown since its inception was -99.37%, roughly equal to the maximum TGTX drawdown of -99.52%. Use the drawdown chart below to compare losses from any high point for RIGL and TGTX.
Loading charts...
Drawdown Indicators
| RIGL | TGTX | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -99.37% | -99.52% | +0.15% |
Max Drawdown (1Y)Largest decline over 1 year | -50.08% | -32.66% | -17.42% |
Max Drawdown (3Y)Largest decline over 3 years | -57.75% | -75.42% | +17.67% |
Max Drawdown (5Y)Largest decline over 5 years | -85.24% | -90.75% | +5.51% |
Max Drawdown (10Y)Largest decline over 10 years | -86.40% | -93.19% | +6.79% |
Current DrawdownCurrent decline from peak | -96.93% | -78.79% | -18.14% |
Average DrawdownAverage peak-to-trough decline | -90.91% | -91.43% | +0.52% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 28.64% | 18.04% | +10.60% |
Volatility
RIGL vs. TGTX - Volatility Comparison
The current volatility for Rigel Pharmaceuticals, Inc. (RIGL) is 12.05%, while TG Therapeutics, Inc. (TGTX) has a volatility of 15.65%. This indicates that RIGL experiences smaller price fluctuations and is considered to be less risky than TGTX based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| RIGL | TGTX | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 12.05% | 15.65% | -3.60% |
Volatility (6M)Calculated over the trailing 6-month period | 36.64% | 34.28% | +2.36% |
Volatility (1Y)Calculated over the trailing 1-year period | 69.89% | 47.22% | +22.67% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 85.46% | 87.77% | -2.31% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 82.81% | 86.88% | -4.07% |
Dividends
RIGL vs. TGTX - Dividend Comparison
Neither RIGL nor TGTX has paid dividends to shareholders.
Financials
RIGL vs. TGTX - Financials Comparison
This section allows you to compare key financial metrics between Rigel Pharmaceuticals, Inc. and TG Therapeutics, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
RIGL vs. TGTX - Profitability Comparison
RIGL - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Rigel Pharmaceuticals, Inc. reported a gross profit of 54.21M and revenue of 58.82M. Therefore, the gross margin over that period was 92.2%.
TGTX - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, TG Therapeutics, Inc. reported a gross profit of 171.41M and revenue of 204.92M. Therefore, the gross margin over that period was 83.7%.
RIGL - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Rigel Pharmaceuticals, Inc. reported an operating income of 11.89M and revenue of 58.82M, resulting in an operating margin of 20.2%.
TGTX - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, TG Therapeutics, Inc. reported an operating income of 34.80M and revenue of 204.92M, resulting in an operating margin of 17.0%.
RIGL - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Rigel Pharmaceuticals, Inc. reported a net income of 8.65M and revenue of 58.82M, resulting in a net margin of 14.7%.
TGTX - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, TG Therapeutics, Inc. reported a net income of 19.78M and revenue of 204.92M, resulting in a net margin of 9.7%.
Frequently Asked Questions
RIGL and TGTX have a correlation of 0.33, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
TGTX has higher volatility (15.65%) compared to RIGL (12.05%). In terms of maximum drawdown, RIGL dropped -99.37% vs TGTX's -99.52%.
RIGL currently has the higher Sharpe Ratio (0.78 vs 0.69), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for RIGL and TGTX
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer